Class information for:
Level 1: ETRAVIRINE//RILPIVIRINE//TMC125

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
21495 359 35.9 73%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
26 34435 ANTIRETROVIRAL THERAPY//HIV//NEVIRAPINE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ETRAVIRINE Author keyword 51 52% 19% 69
2 RILPIVIRINE Author keyword 39 58% 13% 46
3 TMC125 Author keyword 19 71% 4% 15
4 NANOART Author keyword 11 100% 2% 6
5 LERSIVIRINE Author keyword 9 67% 2% 8
6 TMC278 Author keyword 8 60% 3% 9
7 E138K Author keyword 4 75% 1% 3
8 NANOFORMULATED ANTIRETROVIRAL THERAPY Author keyword 4 75% 1% 3
9 NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR NNRTI Author keyword 4 75% 1% 3
10 NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR Author keyword 3 18% 5% 17

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ETRAVIRINE 51 52% 19% 69 Search ETRAVIRINE Search ETRAVIRINE
2 RILPIVIRINE 39 58% 13% 46 Search RILPIVIRINE Search RILPIVIRINE
3 TMC125 19 71% 4% 15 Search TMC125 Search TMC125
4 NANOART 11 100% 2% 6 Search NANOART Search NANOART
5 LERSIVIRINE 9 67% 2% 8 Search LERSIVIRINE Search LERSIVIRINE
6 TMC278 8 60% 3% 9 Search TMC278 Search TMC278
7 E138K 4 75% 1% 3 Search E138K Search E138K
8 NANOFORMULATED ANTIRETROVIRAL THERAPY 4 75% 1% 3 Search NANOFORMULATED+ANTIRETROVIRAL+THERAPY Search NANOFORMULATED+ANTIRETROVIRAL+THERAPY
9 NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR NNRTI 4 75% 1% 3 Search NONNUCLEOSIDE+REVERSE+TRANSCRIPTASE+INHIBITOR+NNRTI Search NONNUCLEOSIDE+REVERSE+TRANSCRIPTASE+INHIBITOR+NNRTI
10 NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR 3 18% 5% 17 Search NON+NUCLEOSIDE+REVERSE+TRANSCRIPTASE+INHIBITOR Search NON+NUCLEOSIDE+REVERSE+TRANSCRIPTASE+INHIBITOR

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TMC125 ETRAVIRINE 54 46% 25% 89
2 DUET 1 38 93% 4% 14
3 EXPERIENCED HIV 1 INFECTED PATIENTS 34 36% 21% 76
4 TMC278 32 80% 6% 20
5 2 DIFFERENT FORMULATIONS 14 100% 2% 7
6 HIV NEGATIVE VOLUNTEERS 11 69% 3% 9
7 NNRTI 10 73% 2% 8
8 TMC125 7 44% 3% 12
9 TRANSCRIPTASE INHIBITOR ETRAVIRINE 7 67% 2% 6
10 RILPIVIRINE 6 32% 4% 16

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor 2013 12 13 62%
Update on rilpivirine: A new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication 2013 6 14 79%
Etravirine A Review of its Use in the Management of Treatment-Experienced Patients with HIV-1 Infection 2012 14 60 53%
Clinical Pharmacokinetics and Pharmacodynamics of Etravirine 2009 42 21 52%
Rilpivirine: A second-generation nonnucleoside reverse transcriptase inhibitor 2012 6 7 71%
Etravirine: A Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Active Against NNRTI-Resistant Strains of HIV 2009 25 20 65%
Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhbitor 2009 28 20 55%
Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review 2012 4 14 71%
Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors 2012 16 74 31%
New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data 2012 11 24 38%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 W ON CHURCHILL WING 2 67% 0.6% 2
2 PERSONALIZED NANOMED 1 18% 1.1% 4
3 CLINICIZZATA MALATTIE INFETT 1 50% 0.3% 1
4 DIREZ MED P IDIO 1 50% 0.3% 1
5 EAST BAY AIDS 1 50% 0.3% 1
6 ENVIRONM BIO GRP 1 50% 0.3% 1
7 EU IST NETWORK GEIE 1 50% 0.3% 1
8 HIV INFECT CARE 1 50% 0.3% 1
9 HPEA MRT 3620 1 50% 0.3% 1
10 HUMAN PHARMACOKINET 1 50% 0.3% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000217072 ATAZANAVIR//RITONAVIR//LOPINAVIR
2 0.0000200316 K65R//TRANSMITTED DRUG RESISTANCE//HIV 1 DRUG RESISTANCE
3 0.0000189907 EFAVIRENZ//CYP2B6//NEVIRAPINE
4 0.0000182774 NNRTIS//REVERSE TRANSCRIPTASE//HIV 1 REVERSE TRANSCRIPTASE
5 0.0000133106 ROYAL FREE HIV MED//CD4 CELL COUNT//X BICHAT MED
6 0.0000122557 HIV 1 INTEGRASE//INTEGRASE//RALTEGRAVIR
7 0.0000073938 KEY ARTICLES//PHARMACEUT LEGISLAT MANAGEMENT MKT//PHARM CLIN ADM SERV
8 0.0000058754 BRAIN TARGETING//SMART DRUG DELIVERY//ANGIOPEP 2
9 0.0000051780 PRE EXPOSURE PROPHYLAXIS//POST EXPOSURE PROPHYLAXIS//TREATMENT AS PREVENTION
10 0.0000046901 ENFUVIRTIDE//GP41//T 20